An Update on the State of Tau Radiotracer Development: a Brief Review

Mol Imaging Biol. 2021 Dec;23(6):797-808. doi: 10.1007/s11307-021-01612-1. Epub 2021 May 13.

Abstract

Evolving scientific evidence has begun to point towards hyperphosphorylated tau as a major neurotoxic component in the pathophysiological development of many major neurodegenerative conditions. In response to a need for accurate and reliable diagnosis and disease monitoring in clinical and trial settings, there has been great effort put into the development of tau radiotracers. While first-generation and second-generation radiotracers have provided a basis for assessing tau, concerns of inadequate specificity and selectivity have continued to motivate further study of these radiotracers and the development of novel radiopharmaceuticals. Given the prospective scientific and clinical value of a valid tau radiotracer, the molecular neuroimaging community must be aware of the most recent developments in the realm of tau radiotracer development. This brief review article will critically overview the most established tau radiotracers and, most importantly, concentrate on the progress of more recently developed tau radiotracers.

Keywords: First generation; Neurodegeneration; Neuroimaging; PET; Radiotracers; Second generation; Tau.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease*
  • Brain / metabolism
  • Humans
  • Positron-Emission Tomography / methods
  • Prospective Studies
  • Radiopharmaceuticals
  • tau Proteins* / metabolism

Substances

  • Radiopharmaceuticals
  • tau Proteins